Trial Summary
What is the purpose of this trial?The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.
Eligibility Criteria
This trial is for individuals with locally advanced pancreatic adenocarcinoma. Specific eligibility details are not provided, but typically participants should meet certain health standards and may be required to have a particular stage of cancer.Inclusion Criteria
Anticipated life expectancy ≥ 12 weeks
I can take care of myself and perform daily activities.
My pancreatic cancer is advanced but has not spread far.
+6 more
Exclusion Criteria
I cannot undergo SBRT, endoscopic ultrasound, or IL-12 injections.
I have had cancer before.
My cancer has spread or worsened after initial treatment.
+5 more
Participant Groups
The study is testing the safety and tolerability of combining Stereotactic Body Radiotherapy (SBRT) with an immunotherapy drug called PCX12, administered directly into the tumor in patients with pancreatic cancer.
1Treatment groups
Experimental Treatment
Group I: PCX-12Experimental Treatment1 Intervention
PCX-12 is an experimental immunotherapy drug that is injected into the pancreatic cancer one time in attempt to stimulate the patient's immune system to fight the cancer.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of RochesterRochester, NY
Loading ...
Who Is Running the Clinical Trial?
Haoming (Carl) QiuLead Sponsor